UK’s NICE recommends AstraZeneca’s olaparib to treat cancer types
2023-04-07
上市批准
Preview
来源: Pharmaceutical Technology
Micrograph showing prostatic acinar adenocarcinoma. Credit: Nephron / commons.wikimedia.org.
The UK’s National Institute for Health and Care Excellence (Nice) has published final draft guidance recommending AstraZeneca’s olaparib to treat early breast cancer and metastatic prostate cancer.
The latest development comes following commercial deals negotiated by NHS England and AstraZeneca for the anti-cancer medicine olaparib.
These deals enabled NICE to recommend the medicine as a clinically and cost-effective option to treat HER2-negative, high-risk early breast cancerHER2-negative, high-risk early breast cancer and previously treated hormone-relapsed metastatic prostate cancer in adults.
NICE medicines evaluation director Helen Knight said: “We know how important it is for people with these types of cancer to have more treatment options that enable them to maintain or improve their quality of life.
“For adults with this type of early breast cancer, being able to have a targeted treatment after surgery and chemotherapy will increase the chance of curing the disease and reduce the likelihood of developing incurable advanced disease.
“Olaparib represents an important development in the treatment of early breast and advanced prostate cancer and today’s announcement addresses a significant need by giving people with these types of cancer access to an effective, targeted treatment.”
The latest decision by NICE reverses its earlier draft decision not to recommend the medicine for adults who already received chemotherapy before or after surgery.
It also updates NICE’s recommendation for olaparib for prostate cancer patients with BRCA1 or BRCA2 mutations.
Given as a tablet, olaparib is a type of targeted anti-cancer medicine called a poly adenosine diphosphate-ribose polymerase (PARP) inhibitorpoly adenosine diphosphate-ribose polymerase (PARP) inhibitor.
Final guidance on olaparib for breast cancer and prostate cancer is expected to be published by NICE in May this year.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。